Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Argento, A Christine, Daniel L. Gilstrap, Scott Shofer, Kamran Mahmood, Kimberly Blackwell, and Momen M. Wahidi. “Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in the Diagnosis of Breast Cancer Thoracic Metastases and Detection of Receptor Discordance..” J Bronchology Interv Pulmonol 25, no. 3 (July 2018): 176–80. https://doi.org/10.1097/LBR.0000000000000476.

PMID
29944588
Full Text

Blackwell, Kimberly, Joseph Gligorov, Ira Jacobs, and Chris Twelves. “The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer..” Clin Breast Cancer 18, no. 2 (April 2018): 95–113. https://doi.org/10.1016/j.clbc.2018.01.006.

PMID
29525430
Full Text

Harbeck, Nadia, Pere Gascón, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, and Kimberly Blackwell. “Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies..” Oncologist 23, no. 4 (April 2018): 403–9. https://doi.org/10.1634/theoncologist.2017-0348.

PMID
29317553
Full Text

Blackwell, K., P. Gascon, A. Krendyukov, S. Gattu, Y. Li, and N. Harbeck. “Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy..” Ann Oncol 29, no. 1 (January 1, 2018): 244–49. https://doi.org/10.1093/annonc/mdx638.

PMID
29091995
Full Text

Shammas, Ronnie L., Eugenia H. Cho, Adam D. Glener, Luke P. Poveromo, Lily R. Mundy, Rachel A. Greenup, Kimberly L. Blackwell, and Scott T. Hollenbeck. “Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis..” J Am Coll Surg 225, no. 6 (December 2017): 731-739.e1. https://doi.org/10.1016/j.jamcollsurg.2017.08.023.

PMID
28985927
Full Text

Narloch, Jessica L., S Harrison Farber, Sarah Sammons, Frances McSherry, James E. Herndon, Jenny K. Hoang, Fang-Fang Yin, et al. “Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis..” Neuro Oncol 19, no. 10 (October 1, 2017): 1391–97. https://doi.org/10.1093/neuonc/nox090.

PMID
28472527
Full Text

Ma, Cynthia X., Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric Winer, et al. “Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer..” Clin Cancer Res 23, no. 19 (October 1, 2017): 5687–95. https://doi.org/10.1158/1078-0432.CCR-17-0900.

PMID
28679771
Full Text

Blackwell, K., P. Gascon, C. M. Jones, A. Nixon, A. Krendyukov, R. Nakov, Y. Li, and N. Harbeck. “Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer..” Ann Oncol 28, no. 9 (September 1, 2017): 2272–77. https://doi.org/10.1093/annonc/mdx303.

PMID
28637287
Full Text

Harbeck, Nadia, Pere Gascon, Clyde M. Jones, Allen Nixon, Andriy Krendyukov, Roumen Nakov, Yuhan Li, and Kimberly Blackwell. “Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials..” Future Oncol 13, no. 16 (July 2017): 1385–93. https://doi.org/10.2217/fon-2017-0041.

PMID
28453299
Full Text

Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, et al. “Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial..” Lancet Oncol 18, no. 6 (June 2017): 732–42. https://doi.org/10.1016/S1470-2045(17)30312-1.

PMID
28526536
Full Text

Pages